{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-205099","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.534334+00:00","generated_at":"2026-05-14T23:22:19.768572+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elegrobart Phase 3 REVEAL-2 meets primary endpoint; proptosis responder rate 50-54% vs 15% placebo (p<0.0001)","bullets":["Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.","Diplopia responder rate 61% (Q4W) vs 38% placebo (p=0.0118); complete resolution 44% vs 25% (p=0.0295).","Elegrobart well tolerated; 91% completed treatment, no treatment-related SAEs, low hearing impairment rates.","BLA submission for elegrobart on track for Q1 2027; veligrotug PDUFA target action date June 30, 2026.","Second positive Phase 3 trial for elegrobart; supports potential first subcutaneous autoinjector for TED."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-205099","json":"https://secwatch.observer/filing/0001193125-26-205099.json","markdown":"https://secwatch.observer/filing/0001193125-26-205099.md","text":"https://secwatch.observer/filing/0001193125-26-205099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/0001193125-26-205099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:22:19.768572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}